[Pubmed] Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOS

[RSS-Bot]

Neurol Sci. 2024 Jul 6. doi: 10.1007/s10072-024-07678-3. Online ahead of print.

ABSTRACT

BACKGROUND: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease characterized by recurrent myelitis and optic neuritis. It is associated with high rates of relapse and disability. The main treatment strategies for acute attacks include intravenous methylprednisolone pulse (IVMP) treatment and rescue treatment with plasma exchange (PLEX). Recently, the blockade of neonatal Fc receptor (FcRn)-IgG interaction has gained momentum as a therapeutic strategy. Efgartigimod, the first approved FcRn inhibitor for treating generalized myasthenia gravis, has shown impressive safety, efficacy, and tolerability, and is being regarded as "PLEX in a bottle".

CASE DESCRIPTION: We report a 65-year-old female patient who was diagnosed with anti-AQP4 antibody positive NMOSD. Add-on treatment with efgartigimod to IVMP and intravenous immunoglobulin (IVIG) at the second acute relapse showed favorable results.

CONCLUSION: This case suggests that efgartigimod is a potentially effective add-on therapy in acute attacks of AQP4-IgG-positive NMOSD.

PMID:38969961 | DOI:10.1007/s10072-024-07678-3


Source: https://pubmed.ncbi.nlm.nih.gov/3896996 ... t9+e462414